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Abstract
Understanding the interplay between intracellular signals initiated by multiple receptor tyrosine kinases (RTKs) to give the
final cell phenotype is a major pharmacological challenge. Retinoic acid (RA)-treatment of neuroblastoma (NB) cells
implicates activation of Ret and TrkB RTKs as critical step to induce cell differentiation. By studying the signaling interplay
between TrkB and Ret as paradigmatic example, here we demonstrate the existence of a cross-talk mechanism between the
two unrelated receptors that is needed to induce the cell differentiation. Indeed, we show that TrkB receptor promotes Ret
phosphorylation by a mechanism that does not require GDNF. This reveals to be a key mechanism, since blocking either
TrkB or Ret by small interfering RNA causes a failure in NB biochemical and morphological differentiation. Our results
provide the first evidence that a functional transactivation between distinct tyrosine kinases receptors is required for an
important physiological process.
Citation: Esposito CL, D’Alessio A, de Franciscis V, Cerchia L (2008) A Cross-Talk between TrkB and Ret Tyrosine Kinases Receptors Mediates Neuroblastoma Cells
Differentiation. PLoS ONE 3(2): e1643. doi:10.1371/journal.pone.0001643
Editor: Edathara Abraham, University of Arkansas, United States of America
Received January 15, 2008; Accepted January 24, 2008; Published February 20, 2008
Copyright:  2008 Esposito et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the European Molecular Imaging Laboratory (EMIL) Network (LSH-2004-503569), by the MIUR-FIRB grant (#RBIN04J4J7),
and by the Associazione Italiana per la Ricerca sul Cancro (AIRC) grant to LC.
Competing Interests: The authors have declared that no competing interests exist.
*E-mail: cerchia@unina.it
Introduction
Receptor tyrosine kinases (RTKs) are transmembrane proteins
that in response to growth factors stimulate intracellular pathways
that control most fundamental cellular processes including the cell
cycle, cell migration, cell metabolism and survival, as well as cell
differentiation and proliferation. All known RTKs become
activated by the selective binding of dimeric ligands to their
extracellular domains, resulting in their dimerization and autopho-
sphorylation [1,2]. However, there is accumulating evidence that
enlarges the traditional view of growth factor receptors activation
in that the receptor may be transactivated and, thus, tyrosine-
phosphorylated by ligands which specifically bind to other
membrane receptors. For example, it has been widely demon-
strated the transactivation of the epidermal growth factor receptor
(EGFR) by agonists for G protein-coupled receptors (GPCRs) and
other extracellular stimuli unrelated to EGF-like ligands [3,4].
Similar to EGFR, it has been shown that activation of Trk
(tropomyosin-related kinase) receptor tyrosine kinases TrkA
(P04629 Swiss-Prot accession number) and TrkB (Q16620 Swiss-
Prot accession number) can also occur via a GPCR mechanism,
without involvement of nerve growth factor (NGF, P01138 Swiss-
Prot accession number) or brain-derived neurotrophic factor
(BDNF, P23560 Swiss-Prot accession number) [5,6,7] thus
indicating alternative modes of stimulating trophic functions in
neuronal cells by linking different receptor signalling pathways.
As first example of intracellular cross-activation between RTKs,
it has been shown that in cultures of sympathetic neurons the NGF
receptor, TrkA, acts on Ret (rearranged during transfection,
P07949 Swiss-Prot accession number) kinase by an intracellular
mechanism that transactivates its catalytic domain whereas doesn’t
require ligand expression [8].
As demonstrated for brain tumor glioblastoma multiforme and
other solid tumours, the co-activation of RTKs limits the efficacy
of therapies targeting single receptors [9], thus a deeper insights in
the inter-RTK signalling pathways is needed to find combination
of therapeutic agents with increased anti-cancer efficacy.
Neuroblastoma is the most common solid tumor of childhood
outside the central nervous system; it is made of neural crest cells
that can occur at any point along the sympathetic ganglia or the
adrenal medulla. Expression of neurotrophin receptors of Trk
family is an important prognostic factor in NB and activation of
different Trk receptors leads to variable clinical presentation and
behaviour of the tumor [10,11]. Differences in the expression
pattern of the receptors or their downstream signalling compo-
nents could in part explain the differences in favourable (in the
case of TrkA) or unfavourable (in the case of TrkB) tumors.
However, the cross-talk between the Trk receptors and other
receptors on cell surface may influence the outcome of the NB
cellular response. In NB cells it has been shown that the stably
transfection of TrkB receptor results in enhancing neuroblastoma
invasiveness via upregulating the expression of hepatocyte growth
factor and its receptor TK, c-Met [12]. The need of cooperation
between TrkA and Ret pathways has been shown in the
HTLA230 neuroblastoma cells as critical to promote neuronal
differentiation [13].
Furthermore, there is evidence in literature indicating that the
Ret and TrkB signal pathways are associated with the process of
NB differentiation [14]. Previous studies have shown that RA
induces the neuronal differentiation of many human neuroblas-
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extension in NB cells (SH-SY5Y, LAN-5 and KCNR cells) which
have endogenous expression of BDNF, via induction of TrkB
expression [15,16]. The existence of an autocrine loop sustained
by RA-treatment and involving increase of TrkB expression and its
activation, has been demonstrated for KCNR cells [15].
Furthermore, in all these cell lines RA also induces Ret tyrosine
kinase receptor expression [17] and we have recently demonstrat-
ed that in SK-N-BE cells, the RA-treatment induces a positive
autocrine loop that sustains Ret activation and downstream
signalling and depends on glial-derived neurotrophic factor
(GDNF, P39905 Swiss-Prot accession number) expression and
release. Ret stimulation in turn is crucial to mediate cell
differentiation [18].
However, even if collectively these data indicate a central role of
TrkB and Ret receptors in RA-induced cell differentiation, a clear
understanding of their respective biological need is still lacking and
the mechanism for their involvement in this process has been
never clarified.
Here, we investigated the mechanism of Ret and TrkB
involvement in differentiation of malignant NB cells. Our results
demonstrate that the RA-induced differentiation of human NB
cells depends on the signalling interplay by TrkB and Ret
receptors. By promoting Ret phosphorylation in a GDNF-
independent manner, the BDNF-stimulated TrkB, causes the
induction of the neurite outgrowth and expression of differenti-
ation-specific molecular markers. This is the first report that
describes the need of a functional transactivation between two
unrelated RTKs to cause the final cell phenotype.
Results
Effects of Ret expression and activation in RA-induced
differentiation of human NB cell lines
In order to dissect the respective roles played by TrkB and Ret
receptors in RA-dependent NB cells differentiation we first
analysed the effects of disabling the function of Ret by small
interfering RNA (siRNA) in SK-N-BE, LAN-5 and SH-SY5Y
cells.
The treatment of the three cell lines with 10 mM RA for 3 days
caused a dramatic increase in Ret protein and autophosphoryla-
tion levels that were reduced to basal upon transfecting with a
siRNA targeting human Ret (Figure 1A, compare lanes 1 and 4 to
lane 2, for the three cell lines), whereas a non-silencing control
siRNA had no effect (compare lane 3 to 2). Interestingly, inhibiting
Ret expression hampered the process of differentiation induced by
RA as assessed by monitoring the levels of two proteins whose
expression is up-regulated upon RA-induced differentiation in
several NB cell lines, the nerve growth factor inducible protein
(VGF) and the growth associated protein 43 (GAP-43) [18,19,20].
As shown in Figure 1B, silencing of Ret resulted in a drastic
inhibition of the RA-dependent induction of VGF and GAP-43
(between 60% to 90–100% of inhibition for the three cell lines), as
expected no effect was observed with the negative control siRNA.
To further confirm that the Ret silencing was correlated with a
significant impairment of the RA-induced NB cells differentiation,
we determined the expression levels of tissue transglutaminase
(tTG) an enzyme whose increase has been reported to mediate
RA-induced cell differentiation in NB cells [18,21,22]. As shown
(Figure 1B), even upon RA-treatment, in the Ret-interfered cells
the levels of tTG were almost undetectable as in the absence of
RA-treatment (compare lanes 4 to 1). In agreement with our
previous findings in SK-N-BE [18] these results demonstrate that
Ret is generally required to the RA-induced differentiation of
human NB cells.
RA induces the expression of BDNF and its receptor TrkB
that mediates NB cell differentiation
In apparent discrepancy with the results reported above, in
human KCNR neuroblastoma cells an autocrine loop involving
the activation of TrkB by its ligand BDNF mediates RA-induced
differentiation [15].
Therefore, we determined whether TrkB receptor was involved in
SH-SY5Y, LAN-5 and SK-N-BE cells responsiveness to RA. To this
aim, we first evaluated the expression levels of TrkB and its primary
ligand BDNF in the three cell lines. As shown in Figure 2A, the cells
express the full-length TrkB and BDNF RNA following RA-
treatment (left panel). Furthermore, SH-SY5Y, LAN-5 and SK-N-BE
cells express low levels of TrkB protein and their ability to express
high levels of the receptor is regulated by RA (right panel).
As previously reported for KCNR cells, we found that in SH-
SY5Y and in LAN-5, the RA-treatment leads to an increase of
TrkB phosphorylation, suggesting that the endogenous BDNF
expressed by these cell lines is sufficient to stimulate the activity of
its own receptor (Figure 2B, compare lane 2 to l, in left and middle
panels). At difference, in SK-N-BE the increase in the level of the
protein following RA-treatment was not accompanied by
detectable stimulation of its activity (compare lane 2 to 1 in right
panel). Furthermore, in agreement with previously report [15], the
TrkB receptor in SH-SY5Y and LAN-5 cells is competent for
exogenous BDNF stimulation (Figure 2C, compare lane 2 to 1 and
lane 4 to 3, respectively). In contrast, in SK-N-BE, phosphoryla-
tion of TrkB was undetectable even in the presence of an acute
stimulation with exogenous BDNF (Figure 2C, compare lane 6 to
5) thus indicating that in this cell line RA induces the expression of
a non-functional TrkB receptor. It has been widely reported that,
in vivo, TrkB is spliced to generate truncated receptors that lack the
cytoplamic kinase domain and that are expressed at different
degrees in NB cells and tumors [23–26].
The truncated isoforms have been shown to act as dominant
inhibitors on BDNF signalling by sequestering the full-length
receptor in non-functional heterodimers [25]. It is plausible that a
similar mechanism of competitive TrkB inhibition by a truncated
isoform could occur in SK-N-BE cells. Whether the 95 kDa-
molecular weight, clearly visible in the immunoblot with TrkB
antibodies (Figure 2A, right panel), corresponds to the truncated
TrkB.T1 isoform remains to be determined.
Next, we wondered whether the RA-mediated TrkB up-
regulation and activation mediate cell differentiation. To this
aim we treated the cells with a specific siRNA for TrkB that
completely blocked the expression of TrkB protein in the three cell
lines (Figure 2B, lanes 4). As shown in Figure 3A, blocking TrkB
expression resulted in the suppression of RA-dependent biochem-
ical differentiation in SH-SY5Y and LAN-5 cells (left and middle
panels) as monitored by the levels of GAP-43, tTG and VGF. In
agreement with the observation that SK-N-BE cells express a non-
functional TrkB (see Figure 2B and C), silencing had no effect in
this cell line (right panel). Furthermore, both in SH-SY5Y and LAN-
5 the extent of inhibition of RA-dependent induction of these same
differentiation markers was comparable to that observed by
interfering with Ret (compare Figure 1B to Figure 3A).
The same behaviour as referred to the biochemical differenti-
ation was also observed by monitoring the neurite outgrowth
following RA-treatment of the three cell lines (Figure 3B to K).
Indeed, as expected, disabling the expression of TrkB completely
blocked the RA-induced neurite outgrowth in SH-SY5Y
(Figure 3D) and LAN-5 (Figure 3G) cells but had no effect on
SK-N-BE cells morphology (Figure 3J).
Taken together, the results demonstrate that disabling the
expression of either Ret or TrkB causes a failure in RA-dependent
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Figure 1. Ret activity is involved in RA-induced NB cell differentiation. (A) and (B) SK-N-BE (left panels), LAN-5 (middle panels) and SH-SY5Y
(right panels) cells were either left untreated (lane 1) or RA-treated (lane 2); RA-treated cells were transfected with Ret specific siRNA (siRNARet in lane
4) or a non-silencing control siRNA (siRNAns in lane 3). C, mock-treated cells. (A) Cell lysates were immunoblotted with anti-pRet or anti-Ret
antibodies. To confirm equal loading the filters were stripped and reprobed with anti-atubulin? antibodies, as indicated. Quantitations are done on
the sum of the two Ret-specific enhanced chemiluminescence bands of 170 and 150 kDa corresponding to different glycosylation states of Ret.
Intensity of bands have been calculated using the NIH Image Program on at least two different expositions to assure the linearity of each acquisition.
Fold values are expressed relative to the reference points, arbitrarily set to 1 (labelled with asterisk). (B) To follow biochemical cell differentiation
lysates were immunoblotted with anti-VGF, anti-GAP-43 or anti-tTG antibodies. The filters were blotted with anti-atubulin? antibodies to normalize
the loaded proteins, as indicated. Quantitation and relative abundances are expressed relative to controls, arbitrarily set to 1 (see A). Blots showni n
(A) and (B) are representative of at least four independent experiments.
doi:10.1371/journal.pone.0001643.g001
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Figure 2. RA-dependent induction of expression and activation of TrkB in NB cells. (A) Left, RNA isolated from RA-treated SH-SY5Y, LAN-5
and SK-N-BE cells was reverse transcribed and amplified as described in Materials and Methods. Samples loaded on the gel are as follows: lanes 1, 2
and 3 amplification of TrkB in SH-SY5Y, LAN-5 and SK-N-BE, respectively; lanes 4, 5 and 6 amplification of BDNF in SH-SY5Y, LAN-5 and SK-N-BE,
respectively; lane 7 markers IX (Roche); lanes 8 to 13, RNA samples as in lanes 1 to 6 but in the absence of RT as negative controls. Right, Lysates from
SH-SY5Y, LAN-5 and SK-N-BE, left untreated or RA-treated, were immunoblotted with anti-TrkB antibodies against the extracellular domain of the
receptor. The molecular weights of full-length TrkB and hypothetical TrkB.T1 isoform are indicated. The membranes were stripped and re-probed
with anti-atubulin? antibodies to control equal loading. Blots shown are representative of at least five independent experiments. (B) SH-SY5Y (left
panels), LAN-5 (middle panels) and SK-N-BE (right panels) cells were left untreated or treated with RA in the absence or in the presence of TrkB siRNA
(siRNATrkB) or the negative control siRNAns, as indicated. Cell lysates were immunoprecipitated with anti-panTrk antibodies and analysed by Western
blotting with anti-pTyr or anti-TrkB antibodies. Blots shown are representative of at least four independent experiments. (C) RA-treated SH-SY5Y, LAN-
5 and SK-N-BE cells were left un-stimulated (lanes 1, 3 and 5) or stimulated with BDNF (lanes 2, 4 and 6). Cell extracts were immunoprecipitated with
anti-panTrk antibodies and immonoblotted with anti-pTyr or anti-TrkB antibodies. Blots shown are representative of at least three independent
experiments. In (A), (B) and (C), quantitation and relative abundances are expressed relative to controls, arbitrarily set to 1 (see legend to Figure 1A).
doi:10.1371/journal.pone.0001643.g002
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Figure 3. TrkB mediates the RA-dependent differentiation in SH-SY5Y and LAN-5. SH-SY5Y (left panels), LAN-5 (middle panels) and SK-N-BE
(right panels) cells were left untreated or treated with RA in the absence or in the presence of siRNATrkB or the negative control siRNAns, as indicated.
(A) Cell lysates were immunoblotted with anti-GAP-43, anti-tTG or anti-VGF antibodies. Equal loading was confirmed by immunoblotting with anti-
atubulin antibodies. Quantitation and relative abundances are expressed relative to controls, arbitrarily set to 1 (see legend to Figure 1A). Blots shown
are representative of at least four independent experiments. (B) to (K): Following RA-treatment, the percentage of neurite outgrowth was calculated
and reported as histogram (K). Data are percentage of neurite bearing cells/total cells analyzed. Columns, average of three independent experiments.
Microphotographs of cells are shown (B to J).
doi:10.1371/journal.pone.0001643.g003
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cooperativecross-talk between TrkBand Ret inneuroblastomacells.
It does exist cooperation between TrkB and Ret to induce
RA-dependent NB differentiation?
Based on the recent findings that demonstrate that TrkA is able
to transactivate Ret [8], we asked whether active TrkB could as
well induce the transactivation of Ret in NB cells.
To this aim, we decided to hamper the function of the TrkB
receptor by siRNA and monitor the level of phosphorylation of
Ret following RA-treatment of SH-SY5Y (Figure 4A, left panel) and
LAN-5 cells (Figure 4A, right panel). As shown, transfecting both the
cell lines with the TrkB-specific siRNA for 72 h inhibits RA-
induced Ret activation, but not expression, at the same extent of
treating the cells with Ret specific siRNA (compare lanes 4 to 5, left
and right panels). As a negative control, a non-related siRNA was
also transfected into the cells that had no visible effects on
phosphorylation (lane 3, left and right panels). In contrast, TrkB
phosphorylation was not affected by inhibition of Ret by siRNA
(data not shown). Thus, these results are compatible with the
existence of a transactivation mechanism triggered by TrkB
activity and acting on Ret in a ligand-independent manner.
As predicted by these results, blocking TrkB activation and in
turn Ret phosphorylation caused a failure in RA-dependent cell
differentiation, monitored as inhibition of the RA-dependent
induction of GAP-43 protein (Figure 4A, left and right panels).
These results strongly indicate that RA-induced overexpression
and activation of TrkB in SH-SY5Y and LAN-5 cells is mediated by
Retactivationandleadstoneuroblastomacellsdifferentiation,indeed
blocking TrkB expression prevents Ret activation and cell differen-
tiation at the same extent reached by silencing the Ret receptor.
Exogenous BDNF stimulation of LAN-5 and SH-SY5Y cells
induces Ret activation
To further confirm that Ret activity in LAN-5 and SH-SY5Y
cells is TrkB-dependent, we asked whether the Ret receptor could
be transactivated by exogenous BDNF addition.
ToincreaseTrkBandRetexpression,LAN-5andSH-SY5Ywere
treated with RA for 72 h and cells were then stimulated with BDNF
(50 ng/ml) for 10 min. As shown in Figure 4B, the BDNF acute
stimulationofthe cells led to anincrease of Ret phosphorylation with
respect tothe un-stimulatedcells of 2.75 and 4.8folds for LAN-5 and
SH-SY5Y cells, respectively (comparelane 3 to 2 and lane 6 to 5). As
expected the BDNF stimulation of the cells does not modify the
expression levels of Ret in RA-treated as well in mock treated cells.
Consistently,the stimulation with BDNF ofSK-N-BEdoesnot affect
the RA-induced phosphorylation of Ret (Figure 4B, compare lane 9
to 8) thus reflecting the absence of a functional TrkB expression in
this cell line (see Figure 2C). This supports our above finding that the
activation of Ret in RA-treated SH-SY5Y and LAN-5 cells is
dependent on TrkB activity.
The cross-talk mechanism stimulating Ret tyrosine kinase
activity is GDNF-independent
We have previously demonstrated that in SK-N-BE cells (lacking
of a functional TrkB receptor) RA-induced differentiation is preceded
by the accumulation of Ret and GDNF, and that Ret activation
depends on the synthesis and the extracellular secretion of GDNF
[18]. For what it concerns LAN-5 and SH-SY5Y cells, our results
indicate that Ret phosphorylation following RA-treatment is due
exclusively or at least in large part to a GDNF-independent
mechanism that requires TrkB activity. To further confirm these
findings we blocked GDNF-dependent activation of Ret by two
different inhibitors: 1) the D4 aptamer, that inhibits Ret activity by
directly binding its extracellular domain [27,18]; 2) a truncated Ret
protein, the EC-Ret
wt peptide, that competes for binding to GDNF,
thus depletingtheculture medium of the functional ligand [28,29,18].
Indeed, if in LAN-5 and SH-SY5Y cells Ret is activated by a GDNF-
independent mechanism, using these molecules should have not to
affect RA-induced Ret phosphorylation and differentiation.
As shown in Figure 5, the treatment of SK-N-BE cells with D4
aptamer (Figure 5A, left panel, lane 3) or the soluble EC-Ret
wt
protein (Figure 5B, left panel, lane 3) strongly inhibited Ret
activation, while, in SH-SY5Y and in LAN-5 cells, any attempt to
interfere with Ret stimulation either by using D4 (Figure 5A, middle
panel, lane 3 and right panel, lane 3, respectively) or EC-Ret
wt
(Figure 5B, middle panel, lane 3 and right panel, lane 3, respectively)
failed and the levels of tyrosine phosphorylated Ret remained
high. In addition, no inhibiting effect was observed by increasing
neither the concentrations nor the incubation time of the aptamer
or of the protein on the cells (not shown). As negative controls, we
used a scrambled sequence of the D4 aptamer (D4Sc in the
Figure 5A) and the recombinant EC-Ret protein lacking of the
domains responsible of the functional interaction between Ret and
the GFRa1/GDNF complex (EC-Ret
1-387 in Figure 5B).
Further, in SH-SY5Y and LAN-5, the cell differentiation was
unaffected by D4 treatment, thus mirroring the activation of Ret.
Indeed, as shown in Figure 5A, in both SH-SY5Y and in LAN-5
cells, VGF and tTG levels were induced by RA and remained high
in presence of D4 (compare lane 3 to 2 in middle and right panels,
respectively). As expected, in SK-N-BE cells D4 inhibited VGF as
well tTG RA-dependent increase (compare lane 3 to 2 in left panel,
and 18).
On the basis of these results it is possible to conclude that in SH-
SY5Y and LAN-5 cells, Ret is activated by a GDNF-independent
mechanism. Furthermore, given that both the aptamer and the
recombinant EC-Ret
wt interfere with Ret dimerization acting by the
outside of the cell membrane, their inability to interfere with Ret
suggests that in these cells, a cross-talk mechanism acting on Ret,
stimulates its tyrosine kinase activity by an intracellular pathway.
Discussion
Receptor tyrosine kinases stimulation is a tightly regulated process
that involves high affinity binding by external ligand polypeptide
growth factors.Even tough this isrecognised asthe mainmechanism
that regulates RTK activity, recent reports indicate that alternative
ways of activation exist that implicate transactivation triggered by
other unrelated membrane receptors in the cytoplasm.
Here we report for the first time that a physiological process, as
the RA-induced differentiation, requires a novel transactivation
mechanism which places Ret tyrosine kinase receptor downstream
of TrkB receptor.
As previously reported [15,17,18] retinoic acid treatment of
several human neuroblastoma cells is rapidly followed by a strong
increase in the expression of both these transmembrane receptors
that become activated in the absence of exogenously added BDNF
and GDNF ligands. Here we show that at difference of SH-SY5Y
and LAN-5 cells, upon RA-treatment, in SK-N-BE the TrkB
protein even increased in expression levels is neither tyrosine
phosphorylated nor competent for BDNF acute stimulation. On
the other hand, Ret is induced and phosphorylated at comparable
levels in the three cell lines.
Furthermore, we demonstrate that a functional TrkB receptor is
needed for RA-mediated cell differentiation, indeed silencing TrkB
causes a failure in morphological and biochemical cell differen-
tiation in SH-SY5Y and LAN-5 whereas no effects were observed
TrkB Transactivates Ret
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the other hand, we show that blocking Ret expression and
activation by siRNA hampers as well the process of differentiation
thus indicating that in LAN-5 and SH-SY5Y cells the concurrent
activity of both receptors is needed for differentiation.
In this scenario, the fact that, in SK-N-BE, cell differentiation
exclusively depends on Ret activation [18] raises the obvious
question of by which mechanism TrkB and Ret cooperate in order
to shift the NB cells toward a differentiated phenotype.
Given that silencing of Ret impairs NB differentiation in the three
cell lines this indicates that Ret signalling is a common critical step
for differentiation. For what it concerns LAN-5 and SH-SY5Y cells,
our results establish that the RA-mediated Ret activation and cell
differentiation are, in turn, dependent on TrkB activity, since
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lation. Furthermore, we can exclude the presence of a GDNF-
dependent mechanism of Ret activation since neither the D4
aptamer nor the EC-Ret
wt soluble protein reveal effective in
inhibiting Ret phosphorylation following RA treatment of LAN-5
and SH-SY5Y cells. Indeed, the D4 aptamer interferes with the
GDNF-mediated Ret dimerization and the EC-Ret
wt molecule
competesforbindingtoGDNFthusdepletingthe culturemedium of
the functional ligand [27,28,29].
Taken together, our findings strongly indicate that at least two
mechanisms can lead to stimulation of Ret activity by RA: the first,
characteristic of SK-N-BE cells, lacking of a functional TrkB
receptor, implicates the expression and secretion in the medium of
GDNF thus providing maintenance of an autocrine loop that
mediates cells differentiation (18 and current results); the second, in
LAN-5 and SH-SY5Y cells, implicates that Ret activation is
mediated by TrkB activity and occurs in the absence of GDNF
stimulation. This indicates that a cross-talk mechanism between
TrkB and Ret is functional in human NB cells. Furthermore, we
show that theBDNFacutestimulation of SH-SY5Y andLAN-5 cells
leads to Ret phosphorylation and transactivation in the absence of
GDNF, thus confirming the existence of such inter-RTK signalling.
Inconclusion here we demonstratethat inthethree NBcelllines,the
RA-dependent Ret activation, both if GDNF-mediated (SK-N-BE)
or TrkB-mediated (SH-SY5Y and LAN-5) is needed to induce cell
differentiation since the outcome of blocking Ret phosphorylation is
a failure in NB cell differentiation.
Two major mechanisms could explain the TrkB-dependent Ret
activation. First, TrkB may heterodimerizes with Ret following
BDNF stimulation. Second, TrkB, once phosphorylated by BDNF
could in turn activate Ret by an intracellular way.
The heterodimerization of the platelet-derived growth factor
receptor with EGFR [30,31] or fibroblast growth factor receptor
[32] and heterodimerization of insulin-like growth factor receptor
and EGFR [33] are examples showing that cross-talk of different
receptors may be mediated, at least in some cases, by their
heterodimerization. This is unlikely to happen between TrkB and
Ret on the basis of the following observations. The D4 aptamer
inhibiting properties base on the capability of the RNA molecule
to fold in a specific three-dimensional shape that binds at high
affinity to Ret monomer and interferes with homodimerization
and activation of the receptor [27]. Therefore, it is plausible that
this molecule once bound to Ret monomer could obstacle as well
Ret/TrkB dimerization. Our result showing that the D4 is unable
to hamper RA-dependent Ret activation and differentiation of
LAN-5 and SH-SY5Y cells, lends support to the second
mechanism.
Furthermore, it has been demonstrated the existence of cross-
talk between the signal pathways mediated by Ret and by another
member of the Trk-family, the TrkA receptor, in developing
sympathetic neurons, whereby increased Ret expression and
phosphorylation takes place as a consequence of TrkA activation
by NGF by intracellular mechanisms [8]. These can include down-
regulation of protein tyrosine phosphatases or up-regulation of
tyrosine kinases acting on Ret and/or up-regulation of adaptor
protein that activates Ret in the absence of GDNF. Work is in
progress to clearly understand the mechanism and molecules
involved in Ret transactivation.
Here we demonstrate that the Ret receptor can be recruited by
the TrkB receptor to function in the NB cells differentiation thus
revealing a novel mechanism of functional cooperation between
receptor tyrosine kinases. The understanding of the functional
interplays between receptor is of major importance for the
rationale design of new therapeutics in cancer.
Materials and Methods
Cell Culture and siRNA transfection
Human NB cell lines SK-N-BE (2), SH-SY5Y and LAN-5
(American Type Culture Collection, Manassas, VA) were grown in
Dulbecco’s modified Eagle medium supplemented with 2 mM L-
glutamine, 10% heat-inactivated fetal bovine serum (Hyclone,
Celbio, South Logan, UT), and 50 mg/ml gentamycin. All-trans
RA (Sigma, St. Louis, MO) was dissolved (10 mM) in DMSO and
diluted at 10 mM-final concentration in serum-containing culture
medium. For BDNF acute stimulations, SH-SY5Y, LAN-5 and
SK-N-BE (900.000 cells/10 cm-plate) were RA-treated for 72 h,
serum starved for 4 h and then incubated for 10 min in the
absence or in the presence of BDNF (Alomone Labs, Jerusalem,
Israel) at a final concentration of 50 ng/ml.
Ret or TrkB gene silencing was established by transfection of
high performance validated Ret siRNA [34] specifically targeting
Ret exon-2 (59-GGGAUGCUUACUGGGAGAAtt39) or TrkB
stealth siRNA (59-AACUUAAGCAGAAACAGCAUUACCA)
custom-designed by Invitrogen, into SK-N-BE(2), SH-SY5Y and
LAN-5 NB cell lines. Cells (35.000 cells per 6 cm plate) were
grown and overlaid with the transfection mixtures containing
100 nM Ret siRNA or 150 nM TrkB siRNA and Lipofectamine
2000 (Invitrogen, Carlsbad, CA) in Opti-MEM I reduced serum
medium (Invitrogen). After 5-h incubation, complete culture
medium containing 10 mM RA was added to the cells and
incubation was prolonged up to 72 h. Controls were performed
using a non-related siRNA that do not lead to the specific
degradation of Ret and TrkB mRNA.
Immunoprecipitation and western blot analysis
Cells were washed twice in ice-cold phospate-buffered saline
(PBS), and lysed in buffer A (50 mM Tris-HCl pH 8.0 buffer
containing 150 mM NaCl, 1% Nonidet P-40, 2 mg/ml aprotinin,
1 mg/ml pepstatin, 2 mg/ml leupeptin, 1 mM Na3VO4). Protein
concentration was determined by the Bradford assay using bovine
serum albumin as the standard. For immunoprecipitation analysis,
cell extracts (500 mg) were incubated with anti-panTrk antibody
(C-14) (Santa Cruz Biotechnology Inc, Santa Cruz CA) for 2 h at
4uC and then immunoprecipitated with protein A/G- agarose
(Santa Cruz Biotechnology Inc, Santa Cruz CA) overnight at 4uC.
Immunoprecipitates were washed three times with buffer A and
denatured in Laemmli buffer for 5 min at 100uC. The cell lysates
or immunoprecipitates were subjected to 8% SDS-PAGE. Gels
were electroblotted into polyvinylidene difluoride membranes
(Millipore Co., Bedford, MA), and filters were probed with the
indicated primary antibodies: anti-Ret (H-300), anti-TrkB (H-181),
anti-VGF (R-15) (Santa Cruz Biotechnology Inc, Santa Cruz CA);
anti-(Tyr-phosphorylated) Ret (referred as pRet) (Cell Signaling,
Beverly, MA); anti-phospho-tyrosine (referred as pTyr) (4G10,
Upstate Biotechnology Incorporated, Charlottesville, VA); anti-
GAP-43 (Zymed Laboratories Inc., South San Francisco, CA);
anti-a-tubulin (DM 1A) (Sigma, St. Louis, MO); anti-tTG
antibodies (kindly provided by G. Peluso CNR, Naples, Italy)
[35]. Proteins were visualized with peroxidase-conjugated second-
ary antibodies using the enhanced chemiluminescence system
(Amersham-Pharmacia Biosciences LTD, Uppsala, Sweden).
Where indicated, filters have been stripped as described [28].
Reverse Transcription-PCR analysis
10
6 NB cells were plated on 10-cm dishes and treated with
10 mM RA for 72 h for analysis of full-length TrkB and BDNF
mRNA. Amplification of glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) was used as control to normalize the levels of
TrkB Transactivates Ret
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extraction kit (Ambion Austin, TX). RNA (5 mg) was reverse
transcribed for 60 min at 42uCi na2 0ml-volume reaction mixture
containing 20 units of Moloney Murine Leukaemia Virus Reverse
Transcriptase (M-MV-RT) (Roche, Basel, Switzerland) and
random hexanucleotides (Amersham Pharmacia). The resulting
cDNA fragments were used as PCR templates.
The following pairs of forward and reverse primer sets were
used for amplification: TrkB, 59-GAGCATCATGTACAG-
GAAAT-39 and 59-CTTGATGTTCTTCCTCATGT-39 (PCR
product size, 235 bp); BDNF, 59-GCAACGGCAACAAACCA-
CAACATTATC-39 and 59-GTCCCTGTATCAAAAGGC-
CAACTGAAG-39 (PCR product size, 492 bp); GAPDH, 59-
CATCAAGAAGGTGAAGC-39 and 59-TCTTACTCCTTG-
GAGGCCAT-39 (PCR product size, 240 bp).
Amplifications were performed by 30 cycles of PCR by using the
following conditions: TrkB: 30 sec at 95uC; 30 sec at 57uCa n d
30 sec at 72uC; BDNF: 1 min at 94uC, 1 min at 60uCa n d2m i na t
72uC; GAPDH: 20 sec at 95uC, 30 sec at 58uCa n d1m i na t7 2 uC.
Neurite Outgrowth Bioassay
NB cells were plated at equal density on 10-cm dishes. To
evaluate the effects of TrkB gene silencing on morphologic cell
differentiation, cells were transfected with TrkB-specific or non-
related siRNA as reported in Cell Culture and siRNA trasfection. At
72 h of RA treatment, at least 15 random fields were
photographed by a phase-contrast light microscope and 50 cells
per frame were counted and scored as having neurites or not. A
neurite was operationally defined as a process outgrowth that was
long more than twice the diameter of cell body.
Inhibitors of GDNF-dependent Ret activation
D4 is a 93-base 29-fluoro-RNA-based aptamer that specifically
bind the extracellular domain of Ret thus interfering with ligand-
induced stimulation of its intrinsic tyrosine kinase activity [18]. A
scrambled sequence of D4 (D4sc) is used as control.
The entire Ret receptor extracellular portion (EC-Ret
wt) and
the protein containing just the first three NH2-terminal cadherin-
like domains of EC-Ret
wt (named EC-Ret
1-387) were produced as
reported previously [28,29].
To assess the effects of RNA aptamers and of EC-Ret proteins
on Ret activity, SK-N-BE, SH-SY5Y and LAN-5 cells (160.000
cells/3.5 cm-plate) were treated for 18 h with 1 ml-culture
medium containing 10 mM RA plus 50 mg of indicated EC-Ret
or 1600 nM of indicated aptamers after a short denaturation-
renaturation step. To evaluate the effects of D4 aptamer on cell
differentiation, cells were incubated in 12-well cell plate with
10 mM RA together with 3 mM aptamer for 72 h. The used RNA
concentrations ensure the continuous presence of a concentration
of at least 200 nM, which takes into account the 6 h-half life of the
D4 aptamer in 10% serum. This concentration is effective in
inhibiting Ret activity as previously reported [18,27].
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